Abstract: The present invention encompasses compounds of the formula (I) wherein the groups R1, Cy, and Y are defined herein, which are suitable for the treatment of diseases related to BTK, process of making, pharmaceutical preparations which contain compounds and their methods of use.

Abstract: A curable coating composition having satisfactory low temperature curing property and fast drying speed while maintaining the flexibility and impact resistance of coating films, and also providing the coating films with good anti-corrosion property and good adhesion to a steel substrate; and a process of preparing the curable coating composition.

Abstract: A novel modified epoxy compound that is capable of providing a coating composition with acceptable viscosity, short tack-free time and thy-hard time, and providing resultant coating films with good impact resistance; a process of preparing the modified epoxy compound; an epoxy resin composition comprising the modified epoxy compound; and a curable coating composition comprising the epoxy resin composition and a curing agent.

Abstract: PSA is delivered to the host by outer membrane vesicles (OMVs), secretion structures that target bacterial molecules to host cells. Purified OMVs direct the in vitro differentiation of functional Tregs with potent suppressive activity in a PSA dependent manner. Treatment of animals with OMVs containing PSA prevents experimental colitis and suppresses pro-inflammatory cytokine responses in the gut, and indicate that compositions, medicaments, and methods useful for the treatment of inflammation, and more particularly, inflammatory bowel diseases.

Abstract: This invention relates to a cardanol modified epoxy resin composition, especially, relates to a cardanol and/or dihydric phenol modified epoxy resin composition, a process making thereof and its application in low VOC high solids coating.

Abstract: A novel epoxy resin composition capable of forming a coating composition with a high volume solids content; a coating composition comprising such novel epoxy resin composition capable of providing a resultant coating films with balanced properties including good flexibility, good chemical resistance, short dry-hard time, desirable hardness, and good anti-corrosion performance; and the process of preparing the compositions.

Abstract: The present invention encompasses compounds of the formula (I) wherein the groups A, Cy, X1 and Y are defined herein, which are suitable for the treatment of diseases related to BTK, process of making, pharmaceutical preparations which contain compounds and their methods of use.

Abstract: This invention relates to a cardanol modified epoxy resin composition, especially, relates to a cardanol and/or dihydric phenol modified epoxy resin composition, a process making thereof and its application in low VOC high solids coating.

Abstract: This invention relates to a cardanol modified epoxy resin composition, especially, relates to a cardanol and/or dihydric phenol modified epoxy resin composition, a process making thereof and its application in a low VOC high solids coating, and a low VOC waterborne coating.

Abstract: An epoxy resin composition including at least one epoxy resin having the Formula (I): where a is an integer from 0 to 5, x is an integer from 3 to 15, y is an integer from 5 to 30, z is 0 or one, b is an integer from 3 to 10, c is an integer from one to 6, R1 is a C6 to C20 cycloalkylene group, and R2 is a saturated C2 to C20 aliphatic hydrocarbon group or a saturated C5 to C20 cycloaliphatic hydrocarbon group; a process for preparing the epoxy resin composition; and a curable coating composition comprising the epoxy resin composition.

Abstract: This invention relates to a cardanol modified epoxy resin composition, especially, relates to a cardanol and/or dihydric phenol modified epoxy resin composition, a process making thereof and its application in low VOC high solids coating.

Abstract: The present invention encompasses compounds of the formula (I) wherein the groups A, Cy, X1 and Y are defined herein, which are suitable for the treatment of diseases related to BTK, process of making, pharmaceutical preparations which contain compounds and their methods of use.

Abstract: A method of increasing the percentage of mouse and human Tregs is provided comprising providing B.fragilis or PSA and vitamin D or vitamin D metabolite to said mouse or human. Also, a method for treating inflammatory bowel diseases in an individual is presented where the individual is given a combination of vitamin D and B. fragilis or PSA. Such a treatment may be particularly effective in individuals who are either Vitamin D insufficient or deficient.

Abstract: A ring-like region excluding a central region and a peripheral region from an image pickup area is preset as a focus area. An image signal is acquired through a lens and a CCD circuit. Based on the image signal thus acquired, a contrast value indicating the degree of in-focus of the preset focus area is calculated. A lens position corresponding to a maximum contrast value of the preset focus area is determined as an in-focus lens position. In autofocus processing, face detection is carried out first. Then, if the result of face detection is successful, a face region is set up as a focus area, and focus adjustment is performed based thereon. Alternatively, if the result of face detection is unsuccessful, focus adjustment is performed based on the preset focus area.

Abstract: PSA is delivered to the host by outer membrane vesicles (OMVs), secretion structures that target bacterial molecules to host cells. Purified OMVs direct the in vitro differentiation of functional Tregs with potent suppressive activity in a PSA dependent manner. Treatment of animals with OMVs containing PSA prevents experimental colitis and suppresses pro-inflammatory cytokine responses in the gut, and indicate that compositions, medicaments, and methods useful for the treatment of inflammation, and more particularly, inflammatory bowel diseases.

Abstract: A ring-like region excluding a central region and a peripheral region from an image pickup area is preset as a focus area. An image signal is acquired through a lens and a CCD circuit. Based on the image signal thus acquired, a contrast value indicating the degree of in-focus of the preset focus area is calculated. A lens position corresponding to a maximum contrast value of the preset focus area is determined as an in-focus lens position. In autofocus processing, face detection is carried out first. Then, if the result of face detection is successful, a face region is set up as a focus area, and focus adjustment is performed based thereon. Alternatively, if the result of face detection is unsuccessful, focus adjustment is performed based on the preset focus area.

Abstract: A method for image linear structure detection in medical imaging. The method includes locating microcalcification (mcc) candidate spots in a mammographic image; forming candidate clusters; assigning ranks to the candidate clusters; identifying linear structures in the neighborhood where the candidate clusters reside; and altering the ranks of the candidate clusters for which linear structures have been identified in the neighborhood.

Abstract: A method for computer-aided detection of microcalcification clusters using a digital computer obtains digital mammography data for a single view image and normalizes and filters the image data to reduce noise. A first mask is generated and applied to the image data for defining the breast structure, forming a first cropped image. A second mask is generated and applied to the image data for defining muscle structure, forming a second cropped image. An artifact mask corresponding to vascular calcifications and known imaging artifacts is generated and applied to the first and second cropped images, defining first and second artifact-masked cropped images. In a repeated sequence, portions of each artifact-masked cropped image are processed using an enhancement algorithm and reducing edge effects to obtain a set of microcalcification cluster candidates and suspected microcalcification clusters.

Abstract: A method and system is presented for screening bacteria, products purified or made by bacteria and/or other bacterial substance for anti-inflammatory ability.

Abstract: A method for computer-aided detection of microcalcification clusters obtains digital mammography data for a single view image and normalizes and filters the image data to reduce noise. A first mask is generated and applied to the image data for defining the breast structure, forming a first cropped image. A second mask is generated and applied to the image data for defining muscle structure, forming a second cropped image. An artifact mask corresponding to vascular calcifications and known imaging artifacts is generated and applied to the first and second cropped images, defining first and second artifact-masked cropped images. In a repeated sequence, portions of each artifact-masked cropped image are processed using an enhancement algorithm and reducing edge effects to obtain a set of microcalcification cluster candidates and suspected microcalcification clusters.